Analysis of the Pregnancy-Maintaining Effect of Allylestrenol in Threatened and Habitual Abortion

Borglin, N. E.; Eliasson, Gösta

doi:10.1016/s0015-0282(16)34623-4

Cited by 8 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Allylestrenol, first introduced in the 1960s, is used for recurrent miscarriage and premature labor prevention [12][13][14]. In China, luteal support is used off-label owing to its significant effects on progesterone receptors, serum estradiol levels, and serum progesterone levels [15].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of allylestrenol for clinical pregnancies in patients treated with assisted reproductive techniques: a retrospective, propensity score matched, observational study

Yu,

Ding

et al. 2023

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

Background Allylestrenol is an oral progestogen being increasingly used for luteal phase support in assisted reproductive techniques. However, evidence of the clinical efficacy of allylestrenol in luteal phase support is lacking. Dydrogesterone is a representative drug used for luteal phase support, the efficacy of which has been clinically confirmed. As such, we aimed to compare the effects of allylestrenol with the standard dydrogesterone on clinical pregnancy rates and pregnancy outcomes. Methods This retrospective study included 3375 assisted reproductive technique cycles using either allylestrenol or dydrogesterone between January 2015 and March 2020. Patients using either allylestrenol or dydrogesterone were matched in a 1:1 ratio using propensity scores. The primary outcomes were clinical pregnancy rate and pregnancy outcomes. Results No significant difference was found in the clinical pregnancy rate (53.5% vs. 53.2%, P = 0.928) and pregnancy outcomes (all P > 0.05) between allylestrenol and dydrogesterone. Compared with dydrogesterone, the use of allylestrenol significantly reduced the rate of biochemical pregnancies (6.4% vs. 11.8%, P < 0.001) and multiple gestation rate (16.8% vs. 26.3%, P = 0.001). Moreover, endometrial thickness, morphology, and blood flow were significantly improved by allylestrenol treatment (all P < 0.05). Conclusions Allylestrenol exhibited similar effects on clinical pregnancy rates and pregnancy outcomes as dydrogesterone. Moreover, allylestrenol can significantly reduce the biochemical pregnancy rate and improve the endometrial receptivity.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of allylestrenol for clinical pregnancies in patients treated with assisted reproductive techniques: a retrospective, propensity score matched, observational study

Yu,

Ding

et al. 2023

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

show abstract

“…Allylestrenol, rst introduced in the 1960s, is used for recurrent miscarriage and premature labor prevention (12)(13)(14). In China, luteal support is used off-label owing to its signi cant effects on progesterone receptors, serum estradiol levels, and serum progesterone levels (15).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of allylestrenol for clinical pregnancies in patients treated with assisted reproductive techniques: a retrospective, propensity score matched, observational study

Ding³

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Allylestrenol is an oral progestogen being increasingly used for luteal phase support (LPS) inassisted reproductive techniques. However, evidence of the clinical efficacy of allylestrenol in LPS is lacking. Dydrogesterone is a representative drug used for LPS, the efficacy of which has been clinically confirmed. As such, we aimed to compare the effects of allylestrenol with the standard dydrogesterone on clinical pregnancy rates and pregnancy outcomes. Methods: This retrospective study included 3375 assisted reproductive technique cycles using either allylestrenol or dydrogesterone between January 2015 and March 2020. Patients using either allylestrenol or dydrogesterone were matched in a 1:1 ratio using propensity scores. The primary outcomes were clinical pregnancy rate and pregnancy outcomes. Results: No significant difference was found in the clinical pregnancy rate (54.4% vs.53.7%, P = 0.787) and pregnancy outcomes (all P > 0.05) between allylestrenol and dydrogesterone. Compared with dydrogesterone, the use of allylestrenol significantly reduced the rate of biochemical pregnancies (6.4% vs.11.8%, P < 0.001) and multiple gestation rate (16.8% vs.26.3%, P = 0.001). Moreover, endometrial thickness, morphology, and blood flow were significantly improved by allylestrenol treatment (all P < 0.05). Conclusions: Allylestrenol exhibited similar effects on clinical pregnancy rates and pregnancy outcomes as dydrogesterone. Moreover, allylestrenol had a more positive impact on biochemical pregnancy and endometrial receptivity.

show abstract

Double-Blind Trial of a Progestin in Habitual Abortion

Goldzieher¹

1964

JAMA

View full text Add to dashboard Cite

Analysis of the Pregnancy-Maintaining Effect of Allylestrenol in Threatened and Habitual Abortion

Cited by 8 publications

References 12 publications

Evaluation of allylestrenol for clinical pregnancies in patients treated with assisted reproductive techniques: a retrospective, propensity score matched, observational study

Evaluation of allylestrenol for clinical pregnancies in patients treated with assisted reproductive techniques: a retrospective, propensity score matched, observational study

Evaluation of allylestrenol for clinical pregnancies in patients treated with assisted reproductive techniques: a retrospective, propensity score matched, observational study

Double-Blind Trial of a Progestin in Habitual Abortion

Contact Info

Product

Resources

About